LDS/Medical Tests/MEK1 Mutation Analysis, Melanoma

MEK1 Mutation Analysis, Melanoma

MEK1 gene encodes for the protein kinase MEK1, a significant enzyme of the mitogen-associated protein kinase (MAPK) signaling pathway. MAPK pathway believed to act as an integration point for numerous extracellular and intracellular signals and elicits cell proliferation, differentiation, and tumorigenesis through sequential activations of the protein kinases and increases DNA transcription. Approximately 1% of human cancer carries a MEK1 mutation.

MEK1 functions at the downstream signals of the MAPK signaling pathway and has a role in the phosphorylation of numerous proteins that increases DNA transcription, protein synthesis, and cellular growth. Various oncogenes activate the MAPK signaling pathway and commonly lead to melanomas. MEK inhibitors target and inhibit MEK1 function, ultimately discontinuing the MAPK pathway, thus used as anti-cancer drugs.

Mutations in the MEK1 gene result in abnormal MEK1 and cause resistance to MEK inhibitors. It means, cancer patients with MEK1 gene mutations will show no response to MEK inhibitors like trametinib and selumetinib. MEK1 mutation commonly coexists with BRAF gene mutation. Nearly 5 % of melanoma patients exhibit resistance to MEK inhibitors. These mutations can be detected by PCR, genomic sequencing, and various molecular techniques.

  • Aids in the diagnosis of MEK1 mutation-related resistance to MEK/ BRAF inhibitors
  • Useful in the selection of appropriate anti-cancer regimens

A positive result indicates the presence of mutation or variants in the MEK1 gene and the possibility of resistance to MEK inhibitors.

A negative result indicates an absence of mutation in the MEK1 gene and no resistance to MEK inhibitors.

Negative for mutations analyzed (No mutations or pathogenic variants in the MEK1 gene were detected).

Real-time Polymerase Chain Reaction (PCR), pyrosequencing, Next-Generation Sequencing (NGS), Multiplex-Ligation dependent Probe Amplification (MLPA), complete genomic sequencing.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unacceptable

Specimen: Solid tumor, Fixative: 10% Formalin

Container: Paraffin-embedded tissue block

Quantity: Two unstained slides and one hematoxylin and eosin-stained slide Store at room temperature.

BRAF gene mutation analysis, skin biopsy, lactate dehydrogenase, complete blood count.
5 to 7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login